Guy Griebel

Summary

Publications

  1. doi Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats
    Guy Griebel
    Sanofi, Exploratory Unit, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France
    Neuropharmacology 70:19-26. 2013
  2. doi Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
    Guy Griebel
    Sanofi, Exploratory Unit, 91385 Chilly Mazarin, France
    Nat Rev Drug Discov 11:462-78. 2012
  3. doi SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents
    Guy Griebel
    Sanofi, Exploratory Unit, Chilly Mazarin, France
    Pharmacol Biochem Behav 102:203-14. 2012
  4. doi The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies
    Guy Griebel
    Sanofi, Exploratory Unit, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France
    J Clin Psychiatry 73:1403-11. 2012
  5. doi Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats
    Guy Griebel
    Exploratory Unit, Sanofi, Chilly Mazarin, France
    Behav Brain Res 232:416-20. 2012
  6. doi Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?
    Guy Griebel
    Sanofi, Chilly Mazarin, France
    Pharmacol Ther 133:116-23. 2012
  7. ncbi Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543
    Carine Dournes
    Sanofi, Exploratory Unit, Chilly Mazarin, France
    Prog Neuropsychopharmacol Biol Psychiatry 40:213-20. 2013
  8. doi The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice
    Alexandre Urani
    Sanofi Aventis, Exploratory Unit, Chilly Mazarin, France
    Pharmacol Biochem Behav 98:425-31. 2011
  9. pmc 50 years of hurdles and hope in anxiolytic drug discovery
    Guy Griebel
    Sanofi, Exploratory Unit, Chilly Mazarin 91385, France
    Nat Rev Drug Discov 12:667-87. 2013
  10. doi SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities
    Denis Boulay
    Sanofi Aventis Research and Development, Exploratory Unit PARIS, 1 Avenue Pierre Brossolette, 91380 Chilly Mazarin, France
    Pharmacol Biochem Behav 97:428-35. 2011

Collaborators

Detail Information

Publications10

  1. doi Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats
    Guy Griebel
    Sanofi, Exploratory Unit, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France
    Neuropharmacology 70:19-26. 2013
    ..These findings confirm further that 5-HT₂A antagonists promote the maintenance of sleep, and suggest that combining a 5-HT₂A antagonist with a short-acting hypnotic may be a useful strategy for the treatment of insomnia...
  2. doi Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
    Guy Griebel
    Sanofi, Exploratory Unit, 91385 Chilly Mazarin, France
    Nat Rev Drug Discov 11:462-78. 2012
    ....
  3. doi SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents
    Guy Griebel
    Sanofi, Exploratory Unit, Chilly Mazarin, France
    Pharmacol Biochem Behav 102:203-14. 2012
    ..o.). Altogether, these findings suggest that SAR110894 may be of therapeutic interest for the treatment of the cognitive symptoms of AD, schizophrenia and certain aspects of ADHD...
  4. doi The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies
    Guy Griebel
    Sanofi, Exploratory Unit, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France
    J Clin Psychiatry 73:1403-11. 2012
    ..These studies were designed to evaluate the efficacy and tolerability of the first nonpeptide vasopressin V(1b) receptor antagonist, SSR149415, in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD)...
  5. doi Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats
    Guy Griebel
    Exploratory Unit, Sanofi, Chilly Mazarin, France
    Behav Brain Res 232:416-20. 2012
    ..In conclusion, this study provides further evidence to support the potential use of H₃ receptor antagonists in the treatment of vigilance and sleep-wake disorders such as narcolepsy...
  6. doi Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?
    Guy Griebel
    Sanofi, Chilly Mazarin, France
    Pharmacol Ther 133:116-23. 2012
    ....
  7. ncbi Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543
    Carine Dournes
    Sanofi, Exploratory Unit, Chilly Mazarin, France
    Prog Neuropsychopharmacol Biol Psychiatry 40:213-20. 2013
    ....
  8. doi The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice
    Alexandre Urani
    Sanofi Aventis, Exploratory Unit, Chilly Mazarin, France
    Pharmacol Biochem Behav 98:425-31. 2011
    ..Together, these data suggest that SSR149415 and SSR125543 may be of interest to reduce the cognitive deficits following exposure to stress-related events, such as acute stress disorder...
  9. pmc 50 years of hurdles and hope in anxiolytic drug discovery
    Guy Griebel
    Sanofi, Exploratory Unit, Chilly Mazarin 91385, France
    Nat Rev Drug Discov 12:667-87. 2013
    ..We highlight various key issues that may have hampered progress in the field, and offer recommendations for how anxiolytic drug discovery can be more effective in the future. ..
  10. doi SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities
    Denis Boulay
    Sanofi Aventis Research and Development, Exploratory Unit PARIS, 1 Avenue Pierre Brossolette, 91380 Chilly Mazarin, France
    Pharmacol Biochem Behav 97:428-35. 2011
    ..These data further strengthen previous findings that the putative atypical antipsychotic SSR181507 has mixed antidepressant and anxiolytic activities...